In a 9-0 decision, the Supreme Court of the United States preserved access to mifepristone, an abortion-inducing medication.
Writing for the court, Justice Brett Kavanaugh determined that the pro-life plaintiffs in the case (FDA v. Alliance for Hippocratic Medicine) do not have the right to challenge the FDA’s regulations allowing access to mifepristone for medicated abortions.
Mifepristone is available in the United States but regulated. It can be prescribed by health care providers who meet certain qualifications and agree to specific requirements set by the FDA. At the beginning of the COVID-19 pandemic, the FDA lift the in-person dispensing requirement for mifepristone, allowing the medication to be sent by mail.
Pharmacies are currently allowed to ship mifepristone after a telemedicine appointment, provided the pharmacy meets specific requirements.
- Certification: The pharmacy must be certified under the Mifepristone REMS (Risk Evaluation and Mitigation Strategy) program.
- Prescription by a Certified Provider: The medication must be prescribed by a health care provider who is certified to prescribe mifepristone under the REMS program.
- Patient Agreement: The patient must sign an agreement form acknowledging the use and risks of mifepristone.
- Counseling and Information: The health care provider must provide counseling on the use of the medication and ensure the patient has access to emergency care if needed.
This is a breaking news story. Please check back for updates.
READ NEXT: Paul Ryan Drops Election Nuke – ‘Anti-Establishment’ Move Shocks Fox News Host
